Danaher Corporation vs Roundhill Innov-100 0DTE Covered Call Strat ETF — how do they compare? Danaher Corporation trades at $219.87 (market cap $152.87B), while Roundhill Innov-100 0DTE Covered Call Strat ETF trades at $29.5 (market cap $962.24M). The key difference: Danaher Corporation is far larger — about 158.9× Roundhill Innov-100 0DTE Covered Call Strat ETF's market cap, and Danaher Corporation pays a 0.74% dividend while Roundhill Innov-100 0DTE Covered Call Strat ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Roundhill Innov-100 0DTE Covered Call Strat ETF for 57 Days on average.
| DHR | QDTE | |
|---|---|---|
Market Cap | $152.87B | $962.24M |
Volume | 5,228,698 | 882,859 |
Sector | Health | Income / Options Overlay |
52-Week High | $242.05 | $36.60 |
52-Week Low | $161.91 | $26.85 |
Typical Hold Time | 69 Days | 57 Days |
Enterprise Value | $175.08B | — |
Dividend Yield | 0.74% | — |
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, down 0.47% on the day, with a bullish technical signal from moving averages and support at $214. The company shows strong profitability with a 58.51% gross margin and has beaten EPS estimates for three consecutive quarters. Recent news includes a declared $0.40 dividend payable in October 2026 and significant institutional buying, such as Bank of America's new $993.8 million stake in Q2 2026.
The outlook is positive with a consensus price target of $230.31, implying 5.9% upside, supported by 70% analyst buy ratings. Risks include elevated valuation multiples like a P/E of 38.76 and fluctuating cash flows, but earnings growth in biotechnology and steady revenue provide a solid foundation for investor confidence.
QDTE (Roundhill Nasdaq-100 0DTE Covered Call Strategy ETF) trades at $29.50, down 1.3% today amid bearish technical signals. The ETF generates weekly income through covered call strategies on Nasdaq-100 components, with recent distributions ranging from $0.11-$0.28. Technical indicators show mixed signals with overall bearish momentum, while fundamental data remains limited for this specialized income-focused product.
The outlook remains cautious as declining volatility pressures distribution yields, with recent payouts suggesting a more sustainable 24-31% annualized yield versus the trailing 43%. Key risks include NAV erosion from return of capital and underperformance in bull markets due to capped upside potential from daily call writing strategies.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →QDTE is an actively managed ETF that seeks to generate income through a covered call strategy on the NASDAQ 100. It primarily holds a portfolio of U.S. government securities and sells 0-DTE (zero days to expiration) index call options on the NASDAQ 100. This highly tactical strategy aims to maximize option premium capture by exploiting the rapid time decay of options expiring on the same day, which provides enhanced income but also exposes the fund to significant volatility and risks associated with daily options settlement.
Read more on QDTE →